Evidence map›Paper›PMID 42775680›Full record

ArticleAging cell2026

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.

Jill de Mol, Daphne H de Korte, Marie A C Depuydt, Virginia Smit, Mireia N A Bernabé Kleijn, Peter J van Santbrink, Christoph J Binder, Florentina Porsch, Frank H Schaftenaar, Amanda C Foks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jill de MolDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-3541-9912
Daphne H de KorteDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0009-0008-6976-5841
Marie A C DepuydtDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-7174-1952
Virginia SmitDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-1181-3122
Mireia N A Bernabé KleijnDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-6027-6154
Peter J van SantbrinkDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Christoph J BinderDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8313-7050
Florentina PorschDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-2633-6632
Frank H SchaftenaarDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
Amanda C FoksDivision of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-9747-3458

Funding

ERA-4HealthEuropean Union 101115159Hartstichting 2018T051Hartstichting 2019T107Hartstichting 2023T138the AtheroNETH consortium, Dutch Heart Foundation 01-001-2024-0601the Treat-ATHERO consortium, Dutch Heart Foundation 02-001-2023-0138
6 · The paper itself

Abstract

Aging is a major risk factor for atherosclerosis and is accompanied by profound changes in the immune system, including effector T cell expansion, senescent cell accumulation, and increased pro-inflammatory signaling. Rapamycin, a promising rejuvenation therapeutic that inhibits mTORC1 and modulates immune aging, was investigated for its potential to attenuate pro-atherogenic immune responses in aged atherosclerotic mice. 80- to 90-week-old male Ldlr

Indexed as

AgingAtherosclerosisInflammationPlaque, AtheroscleroticSirolimusAnimalsMaleMiceSirolimusagingatherosclerosisbasic science researchimmunologysenescencevascular disease

Identifiers

PMID42775680
PMCPMC13599350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.